MCRB News and Press, Seres Therapeutics Inc. From 07/29/25

2025-07-29 14:09:16 ET ... Read the full article on Seeking Alpha For further details see: Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough

2025-07-22 07:57:58 ET More on Seres Therapeutics Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call Transcript Seeking Alpha’s Quant Rating on Seres Therapeutics Historical earnings data for Seres Therapeutics Financial information for Seres Therap...

CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on August 6, 2025 at 8:30 a.m. ET to discuss second quarter 2025 financial...

Thomas DesRosier and Marella Thorell, accomplished biopharma executives, appointed co-CEOs; Eric Shaff stepping down as CEO and will remain a Director on the Seres Board Seres engaging with multiple parties regarding various deal structures, including potential business development and pa...

CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, today announced the Company will be presenting new exploratory biomarker data from its SER-155 Phase 1b study in a poster session at the 2025 ...

2025-05-07 14:18:22 ET Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call May 7, 2025 08:30 ET Company Participants Carlo Tanzi - Investor Relations Eric Shaff - President and Chief Executive Officer Marella Thorell - Chief Financial Officer Matthew Henn -...

2025-05-07 07:08:56 ET More on Seres Therapeutics Seres Therapeutics, Inc. (MCRB) Q4 2024 Earnings Call Transcript Seres Therapeutics, Inc. 2024 Q4 - Results - Earnings Call Presentation Seeking Alpha’s Quant Rating on Seres Therapeutics Historical ear...

BGSF Inc. (BGSF) is expected to report $-0.11 for Q1 2025 Veeco Instruments Inc. (VECO) is expected to report $0.16 for Q1 2025 Bruker Corporation (BRKR) is expected to report $0.46 for Q1 2025 Coeur Mining Inc. (CDE) is expected to report $0.02 for Q1 2025 LifeStance Health Group...

In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignanc...

2025-05-06 12:08:07 ET More on Seres Therapeutics Seres Therapeutics, Inc. (MCRB) Q4 2024 Earnings Call Transcript Seres Therapeutics, Inc. 2024 Q4 - Results - Earnings Call Presentation Seeking Alpha’s Quant Rating on Seres Therapeutics Historical ear...